Results 71 to 80 of about 2,357,394 (215)

Pharmacological and Therapeutic Potential of Garlic (Allium sativum): Integrating Phytochemistry, Molecular Mechanisms, and Clinical and Preclinical Evidence

open access: yesChemistryOpen, Volume 15, Issue 11, November 2026.
Garlic bioactive compounds, including organosulfur compounds (allicin, DADS, DATS, and SAC), phenolic compounds, and quercetin, regulate the Nrf2/HO‐1, NF‐κB, PI3K/Akt, and AMPK/eNOS signaling pathways. These actions enhance antioxidant defenses, suppress inflammation, improve metabolic and cardiovascular function, and contribute to reduced blood ...
Gudisa Bereda
wiley   +1 more source

Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range

open access: yes, 2019
Introduction: Warfarin is an oral anticoagulant that requires ongoing monitoring with time in therapeutic range (TTR), a common measure of the quality of warfarin control and likelihood of adverse events including bleeds.
Bertram, Victoria   +3 more
core   +1 more source

Machine Learning–Augmented Precision Dosing: Integrating Pharmacokinetic Modeling With Clinical Decision Support

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Inter‐individual variability in drug exposure can lead to ineffective therapy or toxicity, particularly in vulnerable patients. Routine model‐informed precision dosing (MIPD) relies mainly on population pharmacokinetic (PopPK) models, Bayesian forecasting, and therapeutic drug monitoring (TDM).
Yunmeng Pang   +5 more
wiley   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

open access: yes, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ   +5 more
core   +1 more source

sj-pdf-1-imr-10.1177_03000605221103959 - Supplemental material for Warfarin resistance: possibilities to solve this problem. A case report

open access: yes, 2022
Supplemental material, sj-pdf-1-imr-10.1177_03000605221103959 for Warfarin resistance: possibilities to solve this problem. A case report by Halyna Mostbauer, Olga Nishkumay, Oksana Rokyta and Valeriia Vavryniuk in Journal of International Medical ...
Valeriia Vavryniuk (12957728)   +3 more
core   +1 more source

Comparative analysis of “APTT vs RVVT” based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation

open access: yesIndian Journal of Pathology and Microbiology, 2020
Background: Thrombophilia is a hypercoagulable state characterized by increased venous thrombosis. The most common cause of heritable thrombophilia is Factor V Leiden (FVR506Q) homozygous state, with a relative risk of 10–80 times as compared to normal ...
Mirza Asif Baig
doaj   +1 more source

Inside the ‘Black Box’ of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulants

open access: yesSociology of Health &Illness, Volume 48, Issue 8, November 2026.
ABSTRACT Sociological interest in pharmaceuticalisation continues to grow, especially regarding the expansion of pharmaceutical use in society. This article presents the first major empirical study focusing on the directionality of pharmaceuticalisation by taking cost‐effectiveness assessment and regulation of anticoagulants in England by the National ...
John Abraham, Gowree Balendran
wiley   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Warfarin-induced deep vein thrombosis

open access: yes, 2014
Khalid A Binymin,1 Magda Nasher,2 Dipti Patel2 1Liverpool University, Medical School, England, UK; 2Southport and Ormskirk NHS Trust, Southport District General Hospital, Kew, UK Abstract: We are presenting a 72-year-old female who was admitted to ...
Patel D, Binymin KA, Nasher M
core  

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy

open access: yesInternational Journal of Hematology-Oncology and Stem Cell Research, 2016
Background: Although catalytic properties of different genetic polymorphisms of VKORC1 and CYP2C9 products have been identified, there is limited study available regarding warfarin dose requirement in Iranian patient population.
Behzad Poopak   +5 more
doaj  

Home - About - Disclaimer - Privacy